Top in hem/onc: Coffee consumption, ASCO guidelines

Coffee consumption may lower the risk for disease progression and death in patients with advanced or metastatic colorectal cancer, according to recently published study results. It was the top story in hematology/oncology last week.

Another top story was about updated guidance from the American Society of Clinical Oncology (ASCO) on chemotherapy-induced peripheral neuropathy.

Read these and more top stories in hematology/oncology below:

Coffee consumption may lower risk for death in advanced, metastatic colorectal cancer

Drinking coffee may reduce the risk for disease progression and death among patients with advanced or metastatic colorectal cancer, according to results of a prospective observational cohort study published in JAMA Oncology. Read more.

ASCO updates guidelines on chemotherapy-induced peripheral neuropathy

Chemotherapy-induced peripheral neuropathy is a potentially debilitating consequence of many cytotoxic drugs for the treatment of cancer. In this article, Charles L. Loprinzi, MD, FASCO, Regis professor of breast cancer research at Mayo Clinic in Rochester, Minnesota, reviews updated guidance from ASCO on chemotherapy-induced peripheral neuropathy and how the recommendations can be applied in clinical practice. Read more.

COVID-19-related surgical delays for early breast cancer may not affect OS, data suggest

Increased time to surgery for ductal carcinoma in situ appeared to be associated with a small increase in pathologic upstaging but did not impact overall survival, according to a retrospective study published in Journal of the American College of Surgeons. Read more.

Link between ibrutinib-related hypertension, heart problems necessitates close monitoring

Ibrutinib (Imbruvica; Janssen, Pharmacyclics) — a Bruton tyrosine kinase inhibitor that inhibits B cell-receptor signaling — has demonstrated long-term efficacy as treatment for many mature B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Although most patients tolerate ibrutinib therapy well, cardiovascular complications — such as hypertension and atrial fibrillation — have emerged as significant treatment-associated adverse events. Read more.

AACR cancer disparities report cites progress, ‘but we still have a long way to go’

The American Association for Cancer Research released its first Cancer Disparities Progress Report, which aims to raise awareness of the substantial effect of cancer on racial and ethnic minorities and other underserved populations. Read more.